TTY Biopharm to Produce to-BBB’s Brain Cancer Candidate

Dutch biotech company to-BBB is enlisting the help of Taiwanese drug formulation firm TTY Biopharm for the future manufacture of clinical-grade brain-targeting doxorubicin liposome candidate for the treatment of brain cancer.

TTY operates an EMEA-approved facility in ChangLi and already manufactures and markets Lipo-Dox®, a pegylated liposomal doxorubicin, in the Taiwanese and Asian markets. The company’s core technologies include liposomal, microemulsion, and sustained-release oral and injectable formulations.

To-BBB’s brain-targeting doxorubicin liposome candidate is currently in preclinical development. The lead product is based on the company’s G-Technology, which involves coating the liposomes with glutathione at the tips of the polyethylene glycol. to-BBB claims the technology improves the safe delivery of free drug to the brain. The G-Technology was originally developed at the Industrial Technology Research Institute in Taiwan.